Risk Breakdown
Financial Exposure
Governance
Double Materiality
Supply Chain
Material Risks
ESG Targets & Commitments
| Topic | Target / Metric | Status |
|---|---|---|
| Human Rights in Supply Chain | HR clauses in all contracts | Commitment |
AI Risk Summary
**MANKIND PHARMA LIMITED – FINANCIAL RISK SUMMARY** Mankind Pharma faces a critical compliance exposure of ₹15–57 crore in estimated remediation costs, driven by a perfect 10.0/10 compliance risk score and uncertain EPR (Extended Producer Responsibility) applicability under SEBI BRSR Core Expansion mandates. The company's failure to report Scope 1 and 2 emissions despite wholesale trading operations creates material disclosure gaps that invite SEBI enforcement action and potential delisting risk for top-tier firms. EPR exposure at 6.5/10 remains a secondary financial pressure, with unquantified product take-back liabilities and packaging compliance obligations likely to emerge as regulatory enforcement tightens around pharmaceutical waste streams. Immediate priority: comprehensive emissions baseline assessment, explicit EPR applicability determination, and documented BRSR P6 compliance framework to mitigate ₹15–57 crore downside and regulatory sanctions.
Source: MANKIND PHARMA LIMITED BRSR Filing, FY -. Derived from the company's own public disclosures. Not investment advice or a regulatory determination.